BUZZ-Nektar wins; Jury rules that Eli Lilly breached contract in drug collaboration dispute

September 25 - **Drug developer Nektar Therapeutics (NKTR.O) shares rose 4% in pre-market trading to $61.80

** Regulatory filings show that a US jury has ruled that Eli Lilly (LLY.N) breached its contractual obligations to Nektar Therapeutics in their prior collaboration on the drug rezpegaldesleukin

** The jury awarded Nektar $90 million in compensation, plus interest to be determined by a judge

** The judgment remains subject to post-trial proceedings and may face an appeal

** Rezpegaldesleukin is an experimental drug Nektar is developing to treat inflammatory skin diseases, and is also Nektar's flagship drug project

** Eli Lilly was previously a development partner for this drug but terminated their collaboration in 2023

** As of the close of the previous trading day, NKTR shares have risen 40% year-to-date

(To facilitate non-native English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may be inaccurate or lack needed context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters accepts no responsibility for any harm or loss arising from the use of the automated translation function.)